Test PD-1 plus chemo-radiation for high-risk nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This Phase 3 trial tests whether adding a PD-1 immunotherapy (given with chemotherapy and radiation, and also after) can improve outcomes for people with high-risk nasopharyngeal cancer. It may help by strengthening the immune system’s attack on the cancer alongside standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have nasopharyngeal cancer confirmed by biopsy, specifically the non-keratinizing type (WHO type II or III).
- Your cancer is stage II–IV based on specific scan results, and you are considered “high-risk” after initial chemotherapy (either by scan response or EBV blood test).
- You are between 18 and 70 years old.
- You are able to do daily activities fairly well (Karnofsky score 70 or higher) and your bone marrow, liver, and kidneys work well enough for treatment.
- You can sign a consent form and meet required blood test standards within 7 days before starting.
- You have not had certain prior treatments or conditions that would interfere with immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 3 trial tests whether adding toripalimab (an immunotherapy medicine) to standard chemo-radiation works better for treating nasopharyngeal cancer that has come back and cannot be removed by surgery. It aims to improve control of the cancer after it returns.
This Phase 3 trial studies whether adding low-dose radiation to cadonilimab (an immune therapy) can improve outcomes for people newly diagnosed with a specific type and stage of nasopharyngeal cancer. If you’re eligible, it may offer a new treatment approach and helps researchers confirm whether it works best.
This trial tests a shorter course of chemotherapy combined with an immunotherapy drug (camrelizumab) for people with advanced nasopharyngeal cancer that hasn't spread to distant organs. The goal is to see if this approach works well while reducing treatment side effects.
This trial tests a new combination of an immunotherapy drug (tislelizumab) plus standard chemoradiotherapy for people with advanced nasopharyngeal carcinoma. It aims to find out if this combination is more effective than standard care alone.
This trial studies whether adding a PD-1 antibody (an immunotherapy) to standard chemoradiation can better control recurrent nasopharyngeal cancer that can’t be removed with surgery. If you qualify, you’d receive the study treatment and be closely monitored for side effects and cancer response.
This trial compares two options—a type of immunotherapy or a chemotherapy pill (capecitabine)—as maintenance treatment after standard chemoradiation for high-risk nasopharyngeal cancer. It aims to see which helps prevent the cancer from coming back.
Hear when a new Nasopharyngeal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.